Incidence and management of hepatic severe veno-occlusive disease in 273 patients in a single centre with defibrotide
Bone Marrow Transplantation2016Vol. 51(9), pp. 1262–1264
Citations Over TimeTop 18% of 2016 papers
Related Papers
- → Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease(2012)47 cited
- → Early Initiation of Defibrotide in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Following Hematopoietic Stem Cell Transplantation Improves Day +100 Survival(2016)2 cited
- → Pooled Treatment Analysis of Pediatric Patients with Defibrotide for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Multi-Organ Dysfunction Following Hematopoietic Stem Cell Transplant(2016)2 cited
- → Pooled Dose Response Analysis of Defibrotide in >1600 Patients for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome(2016)
- → Day+100 Survival and Safety Results from a Defibrotide Expanded-Access Program for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS): Final Results(2017)